RAF1 and neoplasm: As described above, although PF treatment significantly inhibits colorectal cancer cell growth (Figure 2), an unexpected alternative activation of the RAS/RAF/MEK/ERK pathway was observed (Figure 6B; Figure S7, Supporting Information), which would antagonize the anti‐tumor effect of PF.